{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:22:34Z","timestamp":1762842154280,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2018]]},"DOI":"10.1016\/j.ctarc.2018.02.002","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T05:11:48Z","timestamp":1519189908000},"page":"13-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Benefit of crizotinib in a lung cancer patient with discordant ALK testing results"],"prefix":"10.1016","volume":"15","author":[{"given":"Steven","family":"Grocholski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shantanu","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gefei","family":"Qing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David\u00a0E.","family":"Dawe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2018.02.002_bib1","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S1470-2045(11)70232-7","article-title":"Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis","volume":"12","author":"Shaw","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2018.02.002_bib2","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in alk-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2018.02.002_bib3","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3747\/co.20.1568","article-title":"Impact of the college of american pathologists, the international association for the study of lung cancer, and the association for molecular pathology clinical practice guidelines for EGFR and ALK testing in lung cancer In Canada","volume":"20","author":"Ionescu","year":"2013","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ctarc.2018.02.002_bib4","doi-asserted-by":"crossref","DOI":"10.5301\/jbm.5000218","article-title":"ALK immunohistochemistry for ALK gene rearrangement screening in non-small cell lung cancer: a systematic review and meta-analysis","author":"Pyo","year":"2016","journal-title":"Int. J. Biol. Mark."},{"key":"10.1016\/j.ctarc.2018.02.002_bib5","unstructured":"J. Le Quesne, M. Maurya, D. De Castro, S. Popat, A. Wotherspoon, A. Nicholson, A comparison of fish and immunohistochemistry in the detection of ALK rearrangement in lung adenocarcinoma, in: Proceedings of the 15th World Conference On Lung Cancer.1085, 2013."},{"key":"10.1016\/j.ctarc.2018.02.002_bib6","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/his.12708","article-title":"Equivocal ALK fluorescence in-situ hybridization (FISH) cases may benefit from ancillary ALK FISH probe testing","volume":"67","author":"Selinger","year":"2015","journal-title":"Histopathology"},{"key":"10.1016\/j.ctarc.2018.02.002_bib7","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/JTO.0000000000000427","article-title":"A novel, highly sensitive ALK antibody 1A4 facilitates effective screening for ALK rearrangements in lung adenocarcinomas by standard immunohistochemistry","volume":"10","author":"Gruber","year":"2015","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.ctarc.2018.02.002_bib8","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/PAT.0000000000000114","article-title":"Reflex ALK immunohistochemistry is feasible and highly specific for ALK gene rearrangements in lung cancer","volume":"46","author":"Houang","year":"2014","journal-title":"Pathology"},{"key":"10.1016\/j.ctarc.2018.02.002_bib9","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/JTO.0b013e31820b82e8","article-title":"Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization","volume":"6","author":"Paik","year":"2011","journal-title":"J. Thoracic Oncol.: Off. Pub. Int. Assoc. Study Lung Cancer"},{"key":"10.1016\/j.ctarc.2018.02.002_bib10","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2217\/fon.14.275","article-title":"Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach","author":"Salgiam","year":"2015","journal-title":"Fut. Oncol."},{"key":"10.1016\/j.ctarc.2018.02.002_bib11","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/annonc\/mdv240","article-title":"An activating ALK gene mutation in ALK IHC-positive\/FISH-negative nonsmall-cell lung cancer","volume":"26","author":"Togashi","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2018.02.002_bib12","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.jtho.2016.07.012","article-title":"ALK Immunohistochemistry In NSCLC: discordant staining can impact patient treatment regimen","volume":"11","author":"Ibrahim","year":"2016","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.ctarc.2018.02.002_bib13","unstructured":"E. Sugiyama, K. Goto, G. Ishii, Usefulness of IHC for detection of the ALK-fusion gene in non-small cell lung cancer, in: Proceedings of the 15th World Conference On Lung Cancer. 1172, 2013."},{"key":"10.1016\/j.ctarc.2018.02.002_bib14","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3747\/co.23.3120","article-title":"Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer","volume":"23","author":"Melosky","year":"2016","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ctarc.2018.02.002_bib15","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2013.54.5921","article-title":"Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project","volume":"32","author":"Blackhall","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2018.02.002_bib16","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.5858\/arpa.2013-0388-OA","article-title":"ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment","volume":"138","author":"Al\u00ec","year":"2014","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.ctarc.2018.02.002_bib17","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/JTO.0000000000000072","article-title":"Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances","volume":"9","author":"Cabillic","year":"2014","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.ctarc.2018.02.002_bib18","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.7150\/jca.15238","article-title":"Anti-ALK antibodies in patients with ALK-positive malignancies not expressing NPM-ALK","volume":"7","author":"Damm-Welk","year":"2016","journal-title":"J. Cancer"},{"key":"10.1016\/j.ctarc.2018.02.002_bib19","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/annonc\/mdu484","article-title":"Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK borderline-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies","volume":"26","author":"Ilie","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2018.02.002_bib20","first-page":"31","article-title":"A French multicentric and prospective validation study for ALK translocation diagnosis in lung adenocarcinomas","volume":"15","author":"Lantuejoul","year":"2013","journal-title":"Ann. Meet. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2018.02.002_bib21","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jtho.2016.08.145","article-title":"Combinational analysis of FISH and immunohistochemistry reveals rare genomic events in ALK fusion patterns in NSCLC that responds to crizotinib treatment","volume":"12","author":"Li","year":"2017","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.ctarc.2018.02.002_bib22","article-title":"Validation of a new algorithm for a quick and easy RT-PCR-based ALK test in a large series of lung adenocarcinomas: comparison with FISH, immunohistochemistry and next generation sequencing assays","volume":"11","author":"Marchettia","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctarc.2018.02.002_bib23","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1186\/s12885-016-2646-x","article-title":"Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer","volume":"16","author":"Mattsson","year":"2016","journal-title":"BMC cancer."},{"key":"10.1016\/j.ctarc.2018.02.002_bib24","unstructured":"M. Pekar, M. Wynes, M. Ilouze, The hidden 50% of the ALK positive NSCLC patients, in: Proceedings of the 15th World Conference on Lung Cancer.1256, 2013."},{"key":"10.1016\/j.ctarc.2018.02.002_bib25","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.3892\/or.2016.4962","article-title":"ALK ambiguous-positive non-small cell lung cancers are tumors challenged by diagnostic and therapeutic issues","volume":"36","author":"Uguen","year":"2016","journal-title":"Oncol. Reports"},{"key":"10.1016\/j.ctarc.2018.02.002_bib26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/cncy.21510","article-title":"Detection of ALK rearrangements in malignant pleural effusion cell blocks from patients with advanced non-small cell lung cancer: a comparison of Ventana immunohistochemistry and fluorescence in situ hybridization","volume":"123","author":"Wang","year":"2014","journal-title":"Cancer Cytopathol."},{"key":"10.1016\/j.ctarc.2018.02.002_bib27","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/j.jtho.2016.06.001","article-title":"Custom gene capture and next-generation sequencing to resolve discordant ALK status by FISH and IHC in lung adenocarcinoma","volume":"11","author":"Jang","year":"2016","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.ctarc.2018.02.002_bib28","first-page":"698","article-title":"ALK gene rearrangement testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH","volume":"14","author":"Minca","year":"2012","journal-title":"2012 Ann. Meet. Assoc. Mol. Pathol."},{"key":"10.1016\/j.ctarc.2018.02.002_bib29","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/JTO.0000000000000461","article-title":"ALK FISH and IHC: you cannot have one without the other","volume":"10","author":"Yatabe","year":"2015","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.ctarc.2018.02.002_bib30","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.12705","article-title":"ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma","author":"Dacic","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctarc.2018.02.002_bib31","first-page":"32","article-title":"A prospective study to compare qPCR to IHC and FISH for the detection of anaplastic lymphoma kinase (ALK) fusions in FFPE specimens from NSCLC patients (PCRTALK)","volume":"15","author":"Hout","year":"2014","journal-title":"2014 Ann. Meet. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2018.02.002_bib32","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/annonc\/mdv225","article-title":"Reply to the letter to the editor: ALK FISH rearranged and amplified tumor with negative immunohistochemistry: a rare and challenging case concerning ALK status screening in lung cancer by Uguen et al","volume":"26","author":"Ilie","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2018.02.002_bib33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/JTO.0b013e318274694e","article-title":"A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK","volume":"7","author":"Sun","year":"2012","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.ctarc.2018.02.002_bib34","article-title":"Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative","author":"Ma","year":"2016","journal-title":"Oncotarget"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294217300771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294217300771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:17:35Z","timestamp":1762841855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294217300771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":34,"alternative-id":["S2468294217300771"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2018.02.002","relation":{},"ISSN":["2468-2942"],"issn-type":[{"type":"print","value":"2468-2942"}],"subject":[],"published":{"date-parts":[[2018]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefit of crizotinib in a lung cancer patient with discordant ALK testing results","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2018.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}